|
|
Vaccine Comparison
|
BDES-PfCSP (baculovirus dual expression system) |
| Vaccine Information |
- Vaccine Ontology ID: VO_0004801
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Vector:
- Preparation: (Iyori et al., 2013)
- Immunization Route: Intramuscular injection (i.m.)
|
| References |
Iyori et al., 2013: Iyori M, Nakaya H, Inagaki K, Pichyangkul S, Yamamoto DS, Kawasaki M, Kwak K, Mizukoshi M, Goto Y, Matsuoka H, Matsumoto M, Yoshida S. Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein. PloS one. 2013; 8(8); e70819. [PubMed: 23951015].
|
|
ChAd63 -PvTRAP |
| Vaccine Information |
- Vaccine Ontology ID: VO_0004797
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Vector:
- Preparation: (Bauza et al., 2014) the recombinant ChAd63 vectors expressing P. vivax TRAP (PvTRAP).
- Immunization Route: Intramuscular injection (i.m.)
|
| References |
Bauza et al., 2014: Bauza K, Malinauskas T, Pfander C, Anar B, Jones EY, Billker O, Hill AV, Reyes-Sandoval A. Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites. Infection and immunity. 2014; 82(3); 1277-1286. [PubMed: 24379295].
|
|
MVA-PvTRAP |
| Vaccine Information |
- Vaccine Ontology ID: VO_0004796
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Vector:
- Preparation: (Bauza et al., 2014) the recombinant MVA vectors expressing P. vivax TRAP (PvTRAP) .
- Immunization Route: Intramuscular injection (i.m.)
|
| References |
Bauza et al., 2014: Bauza K, Malinauskas T, Pfander C, Anar B, Jones EY, Billker O, Hill AV, Reyes-Sandoval A. Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites. Infection and immunity. 2014; 82(3); 1277-1286. [PubMed: 24379295].
|
|
NILV-Py CSP |
| Vaccine Information |
- Vaccine Ontology ID: VO_0004798
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: None
- Host Species as Laboratory Animal Model: mouse
- Vector:
- Preparation: (Coutant et al., 2012) nonintegrative lentiviral vectors (NILV) encoding Plasmodium yoelii Circumsporozoite Protein (Py CSP), and challenged with sporozoites one month later. 50% (37.5-62.5) of the animals were fully protected. Moreover, protection was long-lasting with 42.8% sterile protection six months after the last immunization.
- Immunization Route: Intramuscular injection (i.m.)
|
| References |
Coutant et al., 2012: Coutant F, Sanchez David RY, Félix T, Boulay A, Caleechurn L, Souque P, Thouvenot C, Bourgouin C, Beignon AS, Charneau P. A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malaria. PloS one. 2012; 7(11); e48644. [PubMed: 23133649].
|
|
NYVAC-CSP (malaria) |
| Vaccine Information |
- Vaccine Ontology ID: VO_0004800
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- Host Species as Laboratory Animal Model: mouse
- Vector:
- Preparation: (Lanar et al., 1996) NYVAC-based vaccinia virus recombinants expressing the circumsporozoite protein (CSP) were evaluated in the Plasmodium berghei rodent malaria model system. Immunization of mice with a NYVAC-based CSP recombinant elicited a high level of protection (60 to 100%).
- Immunization Route: Intramuscular injection (i.m.)
|
| References |
Lanar et al., 1996: Lanar DE, Tine JA, de Taisne C, Seguin MC, Cox WI, Winslow JP, Ware LA, Kauffman EB, Gordon D, Ballou WR, Paoletti E, Sadoff JC. Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infection and immunity. 1996; 64(5); 1666-1671. [PubMed: 8613376].
|
|
rBCGMSP1-15 |
| Vaccine Information |
- Vaccine Ontology ID: VO_0004791
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MSP1-15 as a fusion protein with the α antigen of Mycobacterium kansasii (α-k), which is secreted from the rBCG vaccine vector (Matsumoto et al., 1998).
- MSP1 from P. yoelii str. 17XNL
gene engineering:
- Type: Recombinant vector construction
- Description: A 2.4-kbp fragment containing an α-k–MSP1-15 hybrid gene was subcloned into pSO246. The final construct (designated pSOMSP1-15) was transformed into BCG Tokyo by electroporation (Matsumoto et al., 1998).
- Detailed Gene Information: Click Here.
- Vector:
- Immunization Route: Intravenous injection (i.v.)
|
| References |
Matsumoto et al., 1998: Matsumoto S, Yukitake H, Kanbara H, Yamada T. Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies. The Journal of experimental medicine. 1998; 188(5); 845-854. [PubMed: 9730886].
|
|
SAd-ME.TRAP |
| Vaccine Information |
- Vaccine Ontology ID: VO_0004799
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Vector:
- Preparation: (Reyes-Sandoval et al., 2008) AdC7 and AdC9 elicited strong immunogenicity ( approximately 20% of CD8(+) T cells in spleen), equivalent to or outperforming AdH5 and inducing sterile protection in 92% (C9), 83% (H5 and C7) and 67% (C6) of the mice, providing the first evidence of single-dose protection to Plasmodium berghei.
- Immunization Route: Intramuscular injection (i.m.)
|
| References |
Reyes-Sandoval et al., 2008: Reyes-Sandoval A, Sridhar S, Berthoud T, Moore AC, Harty JT, Gilbert SC, Gao G, Ertl HC, Wilson JC, Hill AV. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. European journal of immunology. 2008; 38(3); 732-741. [PubMed: 18266272].
|
|
